Dose-response modeling in high-throughput cancer drug screenings: An end-to-end approach [article]

Wesley Tansey, Kathy Li, Haoran Zhang, Scott W. Linderman, Raul Rabadan, David M. Blei, Chris H. Wiggins
2020 arXiv   pre-print
Personalized cancer treatments based on the molecular profile of a patient's tumor are an emerging and exciting class of treatments in oncology. As genomic tumor profiling is becoming more common, targeted treatments to specific molecular alterations are gaining traction. To discover new potential therapeutics that may apply to broad classes of tumors matching some molecular pattern, experimentalists and pharmacologists rely on high-throughput, in-vitro screens of many compounds against many
more » ... ferent cell lines. We propose a hierarchical Bayesian model of how cancer cell lines respond to drugs in these experiments and develop a method for fitting the model to real-world high-throughput screening data. Through a case study, the model is shown to capture nontrivial associations between molecular features and drug response, such as requiring both wild type TP53 and overexpression of MDM2 to be sensitive to Nutlin-3(a). In quantitative benchmarks, the model outperforms a standard approach in biology, with ~20% lower predictive error on held out data. When combined with a conditional randomization testing procedure, the model discovers biomarkers of therapeutic response that recapitulate known biology and suggest new avenues for investigation. All code for the paper is publicly available at
arXiv:1812.05691v2 fatcat:j2xr3cciznhe7bkcyyyz6cuyui